Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata

Krueger, Loren; Peterson, Erik; Shapiro, Jerry; Sicco, Kristen Lo

doi:10.1016/j.jdcr.2019.01.006

Cited by 6 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tofacitinib is an oral JAK inhibitor that has shown promising results in treating alopecia areata as with other dermatological diseases [ 1 - 4 , 6 ]. The use of Tofacitinib and other JAK inhibitors for dermatological diseases, especially for AA, is relatively new and yet to be completely evaluated.…”

Section: Discussionmentioning

confidence: 99%

Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study

Alsuhibani,

Alharthi,

AlSuhaymi

et al. 2023

Cureus

View full text Add to dashboard Cite

Introduction Alopecia areata (AA) is a complex autoimmune condition that causes nonscarring hair loss. In Saudi Arabia, AA accounts for 1-2% of new dermatological outpatient visits. It typically presents with sharply demarcated round patches of hair loss and may present at any age. Traditional medical therapies include corticosteroids and immunotherapy. Choosing the ideal treatment depends on multiple factors such as patient age, disease severity, efficacy, side effects, and remission rate. Recent medications that have been used for treating AA are Janus kinase inhibitors. Aim The aim of the study is to assess the awareness and attitude of dermatologists and their use of Tofacitinib in treating AA. Method A cross-sectional study was conducted in 2019 across 14 major cities in Saudi Arabia. A self-administered online questionnaire was specifically developed and used. Dermatologists from government hospitals and private clinics were included through non-probability convenience sampling. The collected data was entered into Microsoft Excel and analyzed using SPSS program version 24. Results In total, out of 546 Dermatologists across Saudi Arabia who responded to the questionnaire, 127 (23.2%) physicians prescribed Tofacitinib in their practice. Out of those who prescribed the drug for AA cases, 58 dermatologists (45.6%) prescribed Tofacitinib after the failure of steroid injections. Among the 127 dermatologists who have utilized Tofacitinib in their practice, 92 (72.4%) believe that Tofacitinib is effective in treating AA. Almost 200 (47.7%) Dermatologists who never prescribed Tofacitinib reported that the main reason was due to the unavailability of the drug in the clinic they were practicing. Conclusions To conclude, out of 546 dermatologists working in Saudi Arabia, 127 (23.2%) prescribe Tofacitinib to treat AA. Ninety-two (72.4%) of the participants reported the effectiveness of Tofacitinib. Two hundred (47.7%) dermatologists who never prescribe Tofacitinib reported that the main reason was due to the unavailability. However, this would raise the need for more research regarding JAK inhibitors generally and Tofacitinib specifically, focusing on the effectiveness versus the side effects of Tofacitinib.

show abstract

Section: Discussionmentioning

confidence: 99%

Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study

Alsuhibani,

Alharthi,

AlSuhaymi

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…[32] It could be used alone or in combination with other drugs such as DPCP, minoxidil, and calcipotriene. [15,30,33] Ozdemir and Balevi found 1% anthralin to be a safe and effective option in treatment-resistant AA in children. [34] TOPICAL ZINC (LOE 1 b)…”

Section: Aa (Loe 4)mentioning

confidence: 99%

Immune-enhancing agents in autoimmune skin diseases – A review

Francis

Jose

2022

JSSTD

View full text Add to dashboard Cite

Immunosuppressive drugs are the main stay of treatment for autoimmune dermatoses. The main disadvantage of these drugs is the increased susceptibility to life-threatening infections. Hence, in recent years, there has been an enthusiastic search for newer groups of drugs that can reduce this risk. Immune enhancing agents are considered as the key players of future. Immune enhancers function by activating various elements of the immune system and thereby amplifying the immune responses. They can be specific or non-specific in action. The main autoimmune dermatoses where the benefits of these drugs have so far been utilized include alopecia areata, vitiligo, psoriasis, lichen planus, and discoid lupus erythematosus. Immunostimulants are available in both topical and systemic forms. Topical immune- enhancing agents include contact sensitizers (diphenylcyclopropenone, dinitrochlorobenzene, and squaric acid dibutyl ester), anthralin, topical zinc, and interferons. Systemic agents include levamisole, zinc, probiotics, and so on. The exact mechanism of action of some of these drugs and other autoimmune conditions where they can be benefited is not completely understood. Another therapeutic agent that may come up in the future is individualized vaccines. Let us look forward to the days when individualized vaccines work wonders in the management of autoimmune diseases.

show abstract

“…To the Editor : The study by Krueger et al 1 presented the combination of anthralin and calcipotriene in the treatment of alopecia areata (AA), and the result was impressive. It may provide us with an alternative approach to tackle treatment-resistant AA when conventional treatments fail.…”

mentioning

confidence: 99%

Combination of topical anthralin and calcipotriene in alopecia areata: A discussion of the mechanisms of action

Yao

2020

JAAD Case Reports

View full text Add to dashboard Cite

Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata

Cited by 6 publications

References 11 publications

Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study

Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study

Immune-enhancing agents in autoimmune skin diseases – A review

Combination of topical anthralin and calcipotriene in alopecia areata: A discussion of the mechanisms of action

Contact Info

Product

Resources

About